|Publication number||USRE41448 E1|
|Application number||US 10/219,998|
|Publication date||20 Jul 2010|
|Filing date||15 Aug 2002|
|Priority date||7 Feb 1997|
|Also published as||DE69829468D1, DE69829468T2, EP0973577A1, EP0973577B1, EP1550479A2, EP1550479A3, US6102884, US6582409, US20070123811, USRE44639, WO1998034676A1|
|Publication number||10219998, 219998, US RE41448 E1, US RE41448E1, US-E1-RE41448, USRE41448 E1, USRE41448E1|
|Inventors||Rafael P. Squitieri|
|Original Assignee||Hemosphere, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (67), Non-Patent Citations (7), Classifications (19), Legal Events (10)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This is a reissue application of U.S. Pat. No. 6,102,884, which issued on Aug. 15, 2000, and which claims benefit under 35 U.S.C. Section 119(e) to U.S. Provisional Patent Application Ser. No. 60/037,094, filed Feb. 3, 1997.
Notice: More than one reissue application has been filed for the reissue of U.S. Pat. No. 6,102,884. The reissue applications are U.S. application Ser. No. 10/219,998 (the present application) and U.S. application Ser. No. 11/417,658, which is a continuation reissue of U.S. Pat. No. 6,102,884.
Currently, HD (hemodialysis) and vascular access for chemotherapy and plasmapheresis is achieved in one of several ways. Applicant's invention involves a new method and instrumentation for HD and vascular access designed to eliminate the problems of the prior methods and create a new, more durable, easier to use, vascular access system.
One prior art method involves a primary arteriovenous fistula. In this method, a native artery is sewn to a native vein creating a high flow system of blood in a vein which over time can be accessed with two hemodialysis needles attached to a dialysis machine. The problem with this method is that few patients are candidates secondary to anatomy and in others the veins or shunt fail to enlarge and mature properly even if the primary fistula remains patent. These arteriovenous fistulas also become aneursymbol over time requiring revision.
Another method involves a subcutaneous prosthetic conduit (PTFE) in the shape of a tube which is sewn at either end to openings made in an artery and vein. This method causes recurrent stenosis at the venous outflow leading to thrombosis (i.e., graft closure) secondary to intimal hyperplasia at venous anastomosis. Thrombosis also occurs at needle puncture sites along the PTFE.
Another method involves a “tunneled” percutaneous dual lumen catheter which is inserted into a central vein. This causes recurrent thrombosis secondary to stasis of blood in the lumen (i.e., not a continuous flow system like an A-V fistula) and build up of fibrinous debris at the venous end. Further, the access end of the catheter protrudes through the skin making it cosmetically unappealing, cumbersome to live with, as well as more likely to become infected.
A further method involves the use of the Sorenson Catheter. This is a percutaneous (not tunneled) dual lumen catheter, placed into the central venous system, which is used to provide temporary access for the purposes of hemodialysis. These catheters are prone to kinking, clotting, infection, and poor flow rates.
A still further method of vascular access involves the “Porta-a-cath”. This system of venous access, which utilizes a subcutaneous reservoir attached to a central venous catheter, is used for long term intervenous access for chemotherapy etc. (It is not intended for HD.) The ports are prone to clotting and must be continually flushed since they are a stagnant system.
Applicant's invention involves a vascular access system, known as the Squitieri Hemodialysis and Vascular Access System, which creates a continuous blood flow and which is easily accessed and resistant to clotting. These advantages provide ideal access for long term HD, chemo or blood draws. An example, would be patients who are on coumadin which require weekly blood draws. This new system becomes less painful over time as the skin over the “needle access” site become less sensitive. The veins are spared repeated blood draws which results in vein thrombosis to such a degree that some patients “have no veins left” making routine blood draws impossible.
Among the more relevant prior art patents are U.S. Pat. Nos. 4,898,669; 4,822,341; 5,041,098; and, 4,790,826. None of the foregoing patents disclose a system having the features of this inventions
A hemodialysis and vascular access system comprises a PTFE end which is sutured to an opening in an artery at one end and the other end is placed into a vein using any technique which avoids the need for an anastomosis between the silicone “venous” end of the catheter and the vein wall. The system comprises any material, synthetic or natural (i.e. vein) which can be sutured to the artery (i.e. preferably PTFE) at one end while the other end is composed of a material which is suitable for placement into a vein in such a way that the openings in the “venous” end of the system are away from the site where the graft enters the vein. The system may also be constructed of multiple layers of materials i.e. PTFE on the inside with silastic on the outside. The “Needle Receiving Site” may also be covered with PTFE to encourage self sealing and tissue ingrowth.
A preferred embodiment comprises a combination of PTFE conduit sewn to an artery on one end of the system with the other end connected to a silastic-plastic catheter which can be percutaneously inserted into a vein via an introducer. The venous end may also be placed via open cut down. The seal around the system where it enters the vein may be “self sealing” when placed in percutaneous technique; it may be achieved with a purse string when done by open technique “cut down”; or, it may be sewn to the vein to create a seal with a “cuff” while the system continues downstream within the venous system to return the arterial blood away from the site of entry into the vein. The entire system can be positioned subcutaneously at the completion of insertion. This design is a significant improvement over existing methods because it avoids the most frequent complication of current HD access methods. By utilizing an indwelling venous end, one avoids creating a sewn anastomosis on a vein which is prone to stenosis secondary to neointimal hyperplasia. By having continuous flow through the silastic end of the catheter, thrombosis of these catheters can be avoided. Dialysis is made more efficient by decreasing recirculation of blood which accompanies the use of side by side dual lumen catheters inserted into a central vein. This invention not only benefits the patient but it also speeds dialysis thus saving time and money.
To summarize, the Squitieri Access System comprises a tube composed of PTFE and a silastic catheter. This tube is used to create an arteriovenous fistulu. The PTFE end (arterial end) of the tube is sewn to an artery while the silastic catheter end is placed into the venous system by the Seldinger technique much like a standard central line. The entire system is subcutaneous at the completion of insertion. This system is a composite of the arterial end of a “gortex graft” joined to the venous end of a “permacath”. This system enjoys strengths of each type of access and at the same time avoids their weaknesses.
Accordingly, an object of this invention is to provide a new and improved vascular access system.
Another object of this invention is to provide a new and improved hemodialysis and vascular access system including an easily replaceable needle receiving site which has superior longevity and performance, is more easily implanted, more easily replaced, and is “user friendly” i.e. easily and safely accessed by a nurse or patient which is ideal for home hemodialysis.
A more specific object of this invention is to provide a new and improved Squitieri hemodialysis and vascular access system including a subcutaneous composite PTFE/Silastic arteriovenous fistula.
A further object of this invention is to provide a new and improved hemodialysis and vascular access system including a fistula utilizing an indwelling silastic end which is inserted percutaneously into the venous system and a PTFE arterial end which is anastomosed to an artery and including a unique needle receiving sites which are positioned anywhere between the ends and which have superior longevity and performance.
A further object of this invention is to provide a system constructed to preserve laminar flow within the system and at the venous outflow end to reduce turbulence and shear force in the vascular system to the degree possible.
A still further object of this invention is to provide a system wherein the arterial end (PTFE) may also be placed by percutaneous technique including one where blood entry holes are distant from the site where blood enters the veins.
The above and other objects of this invention may be more clearly seen when viewed in conjunction with the accompanying drawings wherein:
Referring to the drawings the Squitieri hemodialysis and vascular system, as shown in
The access site 20 includes an in line aperture 16, see
Along the length of the catheter specially constructed access segments 20 are located to receive specially designed needles 15 into the system to gain access to the blood stream which flows through aperture 16. This method avoids perigraft bleeding which leads to thrombosis either by compression of the graft by hematoma or by manual pressure applied to the graft in an attempt to control the bleeding.
The needle access areas 20 which are designed to receive needles 15 etc. to allow access to the system are in line conduits with self-sealing material 17 such as silicone located beneath the skin surface. The silicone member 25 comprises an oval configuration exposed within the frame 26 for ease of puncture. The system may be accessed immediately after insertion without having to wait for the graft to incorporate into the tissues as is the case with the current methods of subcutaneous fistulas. These access areas 20 will protect the graft since they are uniformly and easily utilized requiring little training or experience. The “needle receiving” sites 20 are designed in such a way to preserve laminar flow as far as possible (i.e. not a reservoir arrangement). Needle receiver sites 20 may be connected to a system via “quick couple” 45 for easy exchangability, see FIG. 11.
The free end 19 of the PTFE tube 10 is sewn to an opening in an artery 30, see
In this invention, the materials used may vary as specified herein. The system may be constructed of one or more specific materials. The arteries and veins used may also vary. Material may also be covered with thrombus resistant coatings (heparin, etc.) or biologic tissue. The system may in specific cases be “ringed” for support.
The same concept of using an arterialized venous access catheter may be applied to the use of long term indwelling catheters used to give chemotherapy etc., making the current ports obsolete as these new access systems will have a decreased thrombosis and they will no longer need to be flushed as continuous blood flow through the system makes thrombus formation unlikely. This will definitely cut down on costs since it will decrease nursing requirements in out patient settings, etc.
In alternate embodiments shown in
The upper member 86 includes an oval silicone access site 90 with an outer housing 91 which includes an aperture 92 surrounds the silicone oval 90. This embodiment provides a quick assembly for a needle access site 71.
The Squitieri Hemodialysis/Vascular Access System avoids creation of a venous anastomosis, a revolutionary advancement, i.e. there is no site for neointimal hyperplasia at a venous anastomosis which accounts for the vast majority of PTFE arteriovenous graft failures (60-80%). This is accomplished by returning the blood into a larger vein via an indwelling venous catheter 42. The site of blood return to the venous system is not fixed to the vein wall where neointimal hyperplasia occurs with the standard PTFE bridge graft. This feature represents a tremendous advantage over the present grafts.
As a further advantage, the system is not stagnant and prone to thrombosis, i.e. constant flow through the new system avoids the problem of clotting inherent in indwelling dual lumen venous catheters which remain stagnant when not in use. It also avoids need to flush catheters with heplock thereby reducing nursing costs to maintain the catheter.
The Squitieri system avoids externalization of components which are prone to infection. Since dual lumen catheters exit the skin 14, they frequently lead to sepsis requiring catheter removal despite subcutaneous tunneling. This new access is entirely subcutaneous.
Very importantly the system proposed herein, avoids problems with the aspiration of blood from the venous system and “positional” placement through continuous flow. A frequent problem with dual lumen catheters is their inability to draw blood from the venous system due to clot and fibrinous debris ball-valving at the tip of a catheter. This new system receives blood directly from arterial inflow which ensures high flow rates needed for shorter, more efficient dialysis runs. It also avoids the frequent problem of the catheter tip “sucking” on the vein wall inhibiting flow to the dialysis machine and rendering the access ineffective.
The system avoids recirculation seen with dual lumen catheters resulting in more efficient and more cost effective dialysis.
The system avoids the need for temporary access with incorporation of “Needle Access Sites” 20. A-V fistulas and gortex grafts must “mature” for several weeks before use. This creates a huge strain on the patient as well as the doctor to achieve temporary access while waiting to use the permanent access. Temporary access is very prone to infection, malfunction and vein destruction. By placing sites 20 designed to receive needles 15 along the new access, the system may be used the day it is inserted.
The system avoids PTFE needle site damage with the incorporation of “Needle Access Sites” 20. Needle access directly into PTFE is presently uncontrolled and user dependent. Often, PTFE is lacerated by access needles. While this system may be accessed via the PTFE segment, the needle receiving sites are the preferred method. This leads to excessive bleeding which requires excessive pressure to halt the bleeding causing thrombosis of the graft. “Needle Access Sites” 20 on the Squitieri access system allow safe, quick, and easy entry into the system and avoid the complications inherent in placing needles directly into PTFE. It also avoids perigraft bleeding which will compress and thrombose the graft. By elminating the long time needed to compress bleeding at the needle site, the system shortens dialysis runs.
The Squitieri system permits an easier, faster insertion technique. Only one anastomosis at the arterial end and a percutaneous placement of the venous end is required. A modification allows the system to be sutured to the vein wall while the system tubing is floated down stream from this site where the system enters the vein 40. This saves operating room time at thousands of dollars per hour. The technique is easier with faster replacement. It avoids difficult and time consuming revision of venous anastomosis required to repair venous outflow occluded by neointimal hyperplasia. If the system malfunctions, the silastic catheter end 65 slips out easily and the arterial PTFE end 53 is thrombectomized. New access sewn to the thrombectomized PTFE at the arterial end and the silastic venous end is replaced percutaneously via Seldinger technique or “open technique”.
The end result of the above advantages translates into superior patency rates and a decreased complication rate with this new system. Patients are spared the repeated painful hospitalizations for failed access as well as the emotional trauma associated with this difficult condition. The physicians are spared the dilemma of how to best treat these patients. This system will have a large impact on the current practice of vascular access in areas such as hemodialysis; plasmapheresis; chemotherapy; hyperalimentation; and chronic blood draws.
While the invention has been explained by a detailed description of certain specific embodiments, it is understood that various modifications and substitutions can be made in any of them within the scope of the appended claims which are intended also to include equivalents of such embodiments.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3683926 *||9 Jul 1970||15 Aug 1972||Dainippon Pharmaceutical Co||Tube for connecting blood vessels|
|US3818511||17 Nov 1972||25 Jun 1974||Medical Prod Corp||Medical prosthesis for ducts or conduits|
|US3882862||11 Jan 1974||13 May 1975||Olga Berend||Arteriovenous shunt|
|US4318401 *||24 Apr 1980||9 Mar 1982||President And Fellows Of Harvard College||Percutaneous vascular access portal and catheter|
|US4447237||7 May 1982||8 May 1984||Dow Corning Corporation||Valving slit construction and cooperating assembly for penetrating the same|
|US4496349||26 Oct 1981||29 Jan 1985||Renal Systems, Inc.||Percutaneous implant|
|US4619641||13 Nov 1984||28 Oct 1986||Mount Sinai School Of Medicine Of The City University Of New York||Coaxial double lumen anteriovenous grafts|
|US4822341 *||20 Nov 1987||18 Apr 1989||Impra, Inc.||Vascular access fistula|
|US4877661||19 Oct 1987||31 Oct 1989||W. L. Gore & Associates, Inc.||Rapidly recoverable PTFE and process therefore|
|US4898669 *||13 Jun 1988||6 Feb 1990||Claber S.P.A.||Vascular access device, in particular for purification treatments of the blood|
|US4929236 *||26 May 1988||29 May 1990||Shiley Infusaid, Inc.||Snap-lock fitting catheter for an implantable device|
|US4955899||26 May 1989||11 Sep 1990||Impra, Inc.||Longitudinally compliant vascular graft|
|US5041098||19 May 1989||20 Aug 1991||Strato Medical Corporation||Vascular access system for extracorporeal treatment of blood|
|US5192310 *||16 Sep 1991||9 Mar 1993||Atrium Medical Corporation||Self-sealing implantable vascular graft|
|US5197976 *||16 Sep 1991||30 Mar 1993||Atrium Medical Corporation||Manually separable multi-lumen vascular graft|
|US5399168 *||29 Jul 1992||21 Mar 1995||C. R. Bard, Inc.||Implantable plural fluid cavity port|
|US5476451 *||17 Mar 1995||19 Dec 1995||Michigan Transtech Corporation||Implantable access devices|
|US5558641 *||13 Jan 1995||24 Sep 1996||Sims Deltec, Inc.||Hybrid portal and method|
|US5562618 *||21 Jan 1994||8 Oct 1996||Sims Deltec, Inc.||Portal assembly and catheter connector|
|US5591226||23 Jan 1995||7 Jan 1997||Schneider (Usa) Inc.||Percutaneous stent-graft and method for delivery thereof|
|US5607463||30 Mar 1993||4 Mar 1997||Medtronic, Inc.||Intravascular medical device|
|US5637088 *||14 Sep 1995||10 Jun 1997||Wenner; Donald E.||System for preventing needle displacement in subcutaneous venous access ports|
|US5637102 *||24 May 1995||10 Jun 1997||C. R. Bard, Inc.||Dual-type catheter connection system|
|US5676346 *||29 Aug 1996||14 Oct 1997||Ivac Holdings, Inc.||Needleless connector valve|
|US5743894 *||7 Jun 1995||28 Apr 1998||Sherwood Medical Company||Spike port with integrated two way valve access|
|US5755775 *||3 Sep 1996||26 May 1998||Schneider (Usa) Inc.||Percutaneous stent-graft and method for delivery thereof|
|US5792104 *||10 Dec 1996||11 Aug 1998||Medtronic, Inc.||Dual-reservoir vascular access port|
|US5797879 *||26 Aug 1996||25 Aug 1998||Decampli; William M.||Apparatus and methods for providing selectively adjustable blood flow through a vascular graft|
|US5800512||22 Jan 1996||1 Sep 1998||Meadox Medicals, Inc.||PTFE vascular graft|
|US5830224 *||15 Mar 1996||3 Nov 1998||Beth Israel Deaconess Medical Center||Catheter apparatus and methodology for generating a fistula on-demand between closely associated blood vessels at a pre-chosen anatomic site in-vivo|
|US5840240||3 Nov 1995||24 Nov 1998||Possis Medical, Inc.||Method of making a silicone composite vascular graft|
|US5866217||4 Nov 1991||2 Feb 1999||Possis Medical, Inc.||Silicone composite vascular graft|
|US5904967 *||25 Apr 1996||18 May 1999||Terumo Kabushiki Kaisha||Puncture resistant medical material|
|US5931865||24 Nov 1997||3 Aug 1999||Gore Enterprise Holdings, Inc.||Multiple-layered leak resistant tube|
|US6001125||18 Mar 1998||14 Dec 1999||Meadox Medicals, Inc.||PTFE vascular prosthesis and method of manufacture|
|US6019788 *||4 Nov 1997||1 Feb 2000||Gore Enterprise Holdings, Inc.||Vascular shunt graft and junction for same|
|US6036724||16 Jan 1998||14 Mar 2000||Meadox Medicals, Inc.||PTFE vascular graft and method of manufacture|
|US6102884||7 Apr 1997||15 Aug 2000||Squitieri; Rafael||Squitieri hemodialysis and vascular access systems|
|US6156016||19 Nov 1999||5 Dec 2000||Maginot Vascular Systems||Catheter systems and associated methods utilizing removable inner catheter or catheters|
|US6261255||6 Nov 1998||17 Jul 2001||Ronald Jay Mullis||Apparatus for vascular access for chronic hemodialysis|
|US6338724 *||29 Mar 1999||15 Jan 2002||Christos D. Dossa||Arterio-venous interconnection|
|US6398764 *||27 Dec 1999||4 Jun 2002||Vasca. Inc.||Subcutaneously implanted cannula and method for arterial access|
|US6402767||6 Mar 2000||11 Jun 2002||Kensey Nash Corporation||Anastomosis connection system and method of use|
|US6428571||14 Mar 2000||6 Aug 2002||Scimed Life Systems, Inc.||Self-sealing PTFE vascular graft and manufacturing methods|
|US6582409 *||24 Jan 2000||24 Jun 2003||Graftcath, Inc.||Hemodialysis and vascular access systems|
|US6719783||5 Aug 2002||13 Apr 2004||Scimed Life Systems, Inc.||PTFE vascular graft and method of manufacture|
|US20020049403||5 Sep 2001||25 Apr 2002||Audencio Alanis||Method and apparatus for permanent vascular access for hemodialysis|
|US20030004559||5 Aug 2002||2 Jan 2003||Scimed Life Systems, Inc.||PTFE vascular graft and method of manufacture|
|US20040193242||9 Apr 2004||30 Sep 2004||Scimed Life Systems, Inc.||Self-sealing PTFE vascular graft and manufacturing methods|
|US20040215337||24 Apr 2003||28 Oct 2004||Scimed Life Systems, Inc.||AV grafts with rapid post-operative self-sealing capabilities|
|US20050137614||8 Oct 2004||23 Jun 2005||Porter Christopher H.||System and method for connecting implanted conduits|
|US20050203457||7 Mar 2005||15 Sep 2005||Smego Douglas R.||Apparatus and method for creating an arterio-venous connection in hemodialysis maintenance|
|US20050215938||29 Mar 2004||29 Sep 2005||Iftikhar Khan||Hybrid arteriovenous shunt|
|US20060064159||31 Aug 2005||23 Mar 2006||Porter Christopher H||Device and method for vascular access|
|US20070123811||3 May 2006||31 May 2007||Squitieri Rafael P||Squitieri hemodialysis and vascular access systems|
|US20070167901||16 Nov 2006||19 Jul 2007||Herrig Judson A||Self-sealing residual compressive stress graft for dialysis|
|DE4418910A1||31 May 1994||7 Dec 1995||Mouhamed Kamal Dr Med Koudaimi||Dialysis port system and diaphragm|
|DE29515546U1||29 Sep 1995||30 Jan 1997||Schreiber Hans||Gefäßport, insbesondere für die Hämodialyse|
|JPH0984871A||Title not available|
|JPH04507050A||Title not available|
|JPH05212107A||Title not available|
|JPH06105798A||Title not available|
|JPS5714358A||Title not available|
|JPS58168333A||Title not available|
|WO1984003036A1||26 Jan 1984||16 Aug 1984||Wallsten Hans Ivar||Blood vessel prosthesis|
|WO1995019200A1||17 Jan 1995||20 Jul 1995||Charles David Finch Jr||Implantable vascular device|
|WO1996024399A1||31 Jan 1996||15 Aug 1996||Univ Missouri||Clot resistant multiple lumen catheter|
|1||A.S. Coulson, M.D., Ph.D, Judy Quarnstrom, I.V.N., J. Moshimia, M.D., "A Combination of the Elephant Trunk Anastomosis Techinique and Vascular Clips for Dialysis Grafts," Surgical Rounds, Nov. 1999, pp. 596 to 608.|
|2||Alan S. Coulson, M.D., Jagjit Singh, M.D., Joseph C. Moya, "Modification of Venous End of Dialysis Grafts: An Attempt to Reduce Neointimal Hyperplasia," Dialysis& Transplantation, vol. 29, No. 1, Jan. 2000, pp. 10 to 18.|
|3||International Search Report for PCT Application No. PCT/US98/01939 dated May 5, 1998 in 3 pages.|
|4||Interview Summary dated Mar. 11, 2009 for Co-Pending Appl. No. 11/417,658 in 4 pages.|
|5||Search Report for EP Application No. 05006233.0 dated Jun. 8, 2005 in 2 pages.|
|6||The Amendment dated Mar. 17, 2009 filed in Co-Pending Appl. No. 11/417,658 in 2 pages.|
|7||The Office Action dated Dec. 17, 2008 issued in Co-Pending Appl. No. 11/417,658 in 11 pages.|
|U.S. Classification||604/8, 604/6.01, 604/4.01, 604/5.01|
|International Classification||A61M39/10, A61M5/158, A61M1/14, A61M39/02, A61M1/36, A61M37/00|
|Cooperative Classification||A61M2005/1581, A61M1/3653, A61M2039/0258, A61M2039/0211, A61M1/3655, A61M39/0208|
|European Classification||A61M39/02B, A61M1/36C7, A61M1/36C7A|
|3 Dec 2003||AS||Assignment|
Owner name: GRAFTCATH, INC., WASHINGTON
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SQUITIERI, RAFAEL \\;REEL/FRAME:014181/0902
Effective date: 19991230
|16 Apr 2009||AS||Assignment|
Owner name: HEMOSPHERE, INC., MINNESOTA
Free format text: CHANGE OF NAME;ASSIGNOR:GRAFTCATH, INC.;REEL/FRAME:022562/0278
Effective date: 20080417
|12 Mar 2010||AS||Assignment|
Owner name: HEMOSPHERE MERGER CORP., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HEMOSPHERE, INC.;REEL/FRAME:024079/0130
Effective date: 20100309
|7 Jul 2010||AS||Assignment|
Owner name: HEMOSPHERE, INC., MINNESOTA
Free format text: CHANGE OF NAME;ASSIGNOR:HEMOSPHERE MERGER CORP.;REEL/FRAME:024640/0716
Effective date: 20100311
|22 Feb 2011||CC||Certificate of correction|
|6 Dec 2011||FPAY||Fee payment|
Year of fee payment: 12
|15 May 2012||CC||Certificate of correction|
|17 May 2012||AS||Assignment|
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT, MA
Free format text: SECURITY AGREEMENT;ASSIGNOR:HEMOSPHERE, INC.;REEL/FRAME:028233/0305
Effective date: 20120517
|15 Jan 2015||AS||Assignment|
Owner name: CRYOLIFE, INC., GEORGIA
Free format text: MERGER;ASSIGNOR:HEMOSPHERE, INC.;REEL/FRAME:034723/0198
Effective date: 20141231
|12 Feb 2015||AS||Assignment|
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT, MA
Free format text: SECURITY INTEREST;ASSIGNOR:CRYOLIFE, INC.;REEL/FRAME:034947/0248
Effective date: 20150209